3CS9

Human ABL kinase in complex with nilotinib


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.21 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.197 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E.Manley, P.W.Breitenstein, W.Brueggen, J.Cowan-Jacob, S.W.Ray, A.Huntly, B.Fabbro, D.Fendrich, G.Hall-Meyers, E.Kung, A.L.Mestan, J.Daley, G.Q.Callahan, L.Catley, L.Cavazza, C.Azam, M.Neuberg, D.Wright, R.D.Gilliland, D.G.Griffin, J.D.

(2005) Cancer Cell 7: 129-141

  • DOI: 10.1016/j.ccr.2005.01.007

  • PubMed Abstract: 
  • The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 <30 nM), which is significa ...

    The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 <30 nM), which is significantly more potent than imatinib, and active against a number of imatinib-resistant Bcr-Abl mutants. Crystallographic analysis of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl. Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models. AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.


    Related Citations: 
    • Solution conformations and dynamics of ABL kinase inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib
      Vajpai, N.,Strauss, A.,Fendrich, G.,Cowan-Jacob, S.W.,Manley, P.W.,Grzesiek, S.,Jahnke, W.
      () TO BE PUBLISHED --: --


    Organizational Affiliation

    Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Proto-oncogene tyrosine-protein kinase ABL1
A, B, C, D
277Homo sapiensGene Names: ABL1 (ABL, JTK7)
EC: 2.7.10.2
Find proteins for P00519 (Homo sapiens)
Go to Gene View: ABL1
Go to UniProtKB:  P00519
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
NIL
Query on NIL

Download SDF File 
Download CCD File 
A, B, C, D
Nilotinib
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
C28 H22 F3 N7 O
HHZIURLSWUIHRB-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.21 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.197 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 93.926α = 90.00
b = 118.088β = 90.00
c = 123.683γ = 90.00
Software Package:
Software NamePurpose
REFMACphasing
REFMACrefinement
SCALEPACKdata scaling
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2008-04-22
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance